Therapeutics

Tools

Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
For
ABBV-916 N3pG-Abeta mAb Alzheimer's Disease (Phase 2) Amyloid-Related Immunotherapy (passive)
Donanemab N3pG-Aβ Monoclonal Antibody,
LY3002813
Alzheimer's Disease (Phase 3) Eli Lilly & Co. Amyloid-Related Immunotherapy (passive)
Gamunex Intravenous Immunoglobulin,
Human Albumin Combined With Flebogamma
Alzheimer's Disease (Phase 2/3) Grifols Biologicals Inc. Amyloid-Related, Inflammation Combination, Immunotherapy (passive) Immunodeficiency, chronic inflammatory demyelinating neuropathy
Remternetug LY3372993,
N3pG-Abeta mAb
Alzheimer's Disease (Phase 3) Eli Lilly & Co. Amyloid-Related Immunotherapy (passive)